CBAY — CymaBay Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.73bn
- $3.44bn
- $31.07m
Brief: Cymabay Therapeutics Announces Collaboration With Kaken Pharmaceutical To Develop And Commercialize Seladelpar In Japan For Primary Biliary Cholangitis
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
Cymabay Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: CymaBay Reports Third Quarter And Nine Months Ended Sept 30 Financial Results
Cymabay Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Cymabay Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Cymabay Therapeutics Presents Additional Analyses From Clinical Studies Of Seladelpar For Patients With Primary Biliary Cholangitis At The Liver Meeting 2022
Cymabay Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cymabay Reports Second Quarter And Six Months Ended June 30, 2022 Financial Results And Provides Corporate Update
Cymabay Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
CymaBay up on completing enrollment in key liver disease therapy study
Brief: Cymabay Completes Enrollment For Response Global Phase 3 Study Evaluating Seladelpar For Patients With Primary Biliary Cholangitis
U.S. RESEARCH ROUNDUP-Humacyte, Hyatt Hotels, Poseida Therapeutics
Brief: Cymabay Reports First Quarter 2022 Financial Results And Provides Corporate Update
Cymabay Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Cymabay Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: CymaBay Reports Q4 And Year Ended Dec 31, 2021 Results
Cymabay Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: TCG Crossover Management LLC Reports 7% Passive Stake In Cymabay Therapeutics